UCB SA (OTCMKTS:UCBJY – Get Free Report)’s share price hit a new 52-week high during trading on Tuesday . The company traded as high as $98.65 and last traded at $98.59, with a volume of 9802 shares changing hands. The stock had previously closed at $97.31.
UCB Stock Up 0.5 %
The business has a fifty day simple moving average of $92.48 and a 200 day simple moving average of $81.15. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Read More
- Five stocks we like better than UCB
- What is the Shanghai Stock Exchange Composite Index?
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Breakout Alert: Qualcomm Just Hit The Rally Button
- How Investors Can Find the Best Cheap Dividend Stocks
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
